A Phase 3, Double-Blind, Placebo-Controlled Study of an Investigational Medication as Adjunctive Therapy in Major Depressive Disorder
This is an 18- to 19-week study in patients with major depressive disorder who have an inadequate response to certain other antidepressants. The study will include a one- to two-week screening period, followed by an eight-week, open-label period of treatment with an antidepressant, followed by an eight-week, double-blind treatment period with the investigational medication or placebo added to the antidepressant therapy, followed by a one-week safety follow-up period. A 26-week open-label extension study may also be available to those who complete the lead-in study.
You may be eligible to participate in this study if you:
- Are 18-65 years of age
- Have major depressive disorder, with current episode lasting between two and 12 months
- Have failure to an adequate trial of an antidepressant during the current depressive episode
You will be excluded from this study if you:
- Have certain other diagnoses
- Have a history of ECT and/or certain other treatments during the current episode or within 6 months of study
- Have current, or history of, substance use or dependence
- Have certain other medical conditions
- Have current, or history of, cataracts, eye surgery, laser treatment
This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via e-mail, please include the title of the study in your message.